Live Vaccines Market is Expected to Reach USD 24.95 Billion by the year 2026 | Top Key Players Merck & Co., GlaxoSmithKline plc., Pfizer Inc., Astellas Pharma Inc

According to the current analysis of Reports and Data, the global Live vaccines market was valued at USD 15.15 billion in 2018 and is expected to reach USD 24.95 billion by the year 2026, at a CAGR of 6.6%. Live vaccines are derived from disease causing viruses or bacterial strains, these diseases causing bodies are attenuated or weekend by repeated culturing, which is then replicates into the individual body once is injected in response body develops immune and targets the infectious disease.

This report covers the recent COVID-19 incidence and its impact on Live Vaccines Market. The pandemic has widely affected the economic scenario. This study assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the market.

To Request for a PDF Sample, Click Here: - https://www.reportsanddata.com/sample-enquiry-form/2078

Companies Considered and profiled in this market study

Merck & Co., GlaxoSmithKline plc., Pfizer Inc., Astellas Pharma Inc., Emergent BioSolutions, AstraZeneca plc, Serum Institute of India Pvt. Ltd., Bharat Biotech, Sun Pharmaceutical Industries Limited, Cipla Limited are dominating players in the market and are the companies considered for this report.

The live vaccines market is driven due to the increasing prevalence of infectious disease such as typhoid, across the globe. As per an estimation, around 11-21 million new cases of typhoid are registered worldwide. Approximately 10.0 million cases across the globe, were diagnosed with tuberculosis in 2017. Rising awareness among the public as well as favorable government initiatives is supporting the market growth in developing nations. For example, Indian government started Pulse Polio in India, which aims to approach 100% population irrespective of literacy, financial capability, and to all geographical regions of India by aiming majorly social media.

Global Polio Eradication Initiative (GEPI) funds are managed by various public and private sector donors. Furthermore, according to the recent news, England is no more measles free state due to approximately 931 new cases were registered in England and Wales in 2018 and around 231 new cases in England were diagnosed with measles in the first quarter of 2019. The global burden of such diseases is contributing towards the growth of live vaccines market.

For the purpose of this report, Reports and Data has segmented the live vaccines market on the basis of type, route of administration, application, patient use and region:

Type Outlook (Revenue, USD Million; 2016-2026)

• Viral
• Bacterial

Route of Administration Outlook (Revenue, USD Million; 2016-2026)

• Oral
• Injection
• Intra-Nasal
• Combination of Injection and Oral
• Patch
• Inhalation

Patient Use Outlook (Revenue, USD Million; 2016-2026)

• Adults
• Children

Grab Your Report at an Impressive Discount! Please Click Here @ https://www.reportsanddata.com/discount-enquiry-form/2078

Application Outlook (Revenue, USD Million; 2016-2026)

• Measles
• Mumps
• Rubella
• Varicella
• Yellow Fever
• Rotavirus
• BCG
• Vaccinia
• Influenza
• Typhoid
• Oral Polio
• Smallpox
• Chickenpox
• Others

Regional Outlook (Revenue in USD Million; 2016–2026)

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America

Further key findings from the report suggest

• The measles segment dominates the market with a 24.8% market share in the year 2018. It is estimated to grow at a CAGR of 7.1% during the forecast period to reach USD 6.41 billion by 2026, as more number of patients are suffering from measles

• During 2019-2026, live vaccines market is expected to register a CAGR of 2% in Asia Pacific; followed by North America and Europe, with 6.4% and 6.5% CAGR, respectively. High prevalence of infectious diseases across the globe is the major factor driving the market during the forecast period across all regions.

• Based on type, the viral type of live vaccines segment dominates the market holding over 60% market share.

• The injection route for the administration of live vaccines segment is forecasted to be the fastest growing market segment, estimated to witness a CAGR of 6.8%. Parenteral route or injection for the administration is required for vaccines that cannot be administered orally, due to the factors such as destruction of vaccine by digestive enzymes.

• Asia Pacific accounted for the USD 3.44 billion of the global live vaccines market. Developing nations such China, and India are likely to witness high growth due to high population growth, high geriatric population in the region, and high prevalence of target diseases in the region

• Key players operating in live vaccines market are enhancing their market business through inorganic strategies such as geographic expansion. For instance, in 2019, Sanofi Pasteur started its new state-of-the-art YF-VAX (Yellow Fever Vaccine) production plantation in U.S.

• Slow rate of commercialization, high costs involved in research and development, reluctance toward the adoption of new treatment practices and stringent government regulations are among the key factors likely to hamper growth of the market

Access the Entire Report packed with TOC, Tables and Figures and Outline of Prominent Companies @ https://www.reportsanddata.com/report-detail/live-vaccines-market

Key selling points of this research study

1. The study gives an in-depth evaluation of the evolving competitive scenario that gives the reader/client a competitive edge.

2. It offers a holistic view of all critical aspects boosting or limiting the growth of the sector

3. The market intelligence report derives an eight-year forecast, including historical, contemporary, and potential market prospects, projecting the estimated progress of the market.

4. It aids informed decision-making by offering an exhaustive database of the pivotal market segments and sub-segments.

Contact Us:

John Watson
Head of Business Development
Reports and Data
40 Wall St. 28th floor New York City, NY 10005 United States
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

This release was published on openPR.